UBS Oncology Impact Fund L.P. - Aug 23, 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P
Stock symbol
CGEM
Transactions as of
Aug 23, 2021
Transactions value $
-$3,101,344
Form type
4
Date filed
8/25/2021, 07:42 PM
Previous filing
Aug 12, 2021
Next filing
Sep 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$1.55M -53.4K -0.67% $29.11 7.86M Aug 23, 2021 Direct F1, F2, F3, F4
transaction CGEM Common Stock Sale -$1.5M -50.8K -0.65% $29.48 7.81M Aug 24, 2021 Direct F1, F3, F4, F5
transaction CGEM Common Stock Sale -$49.8K -1.71K -0.02% $29.09 7.81M Aug 25, 2021 Direct F1, F3, F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.
F4 Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.